Meena B. Bansal

7.7k total citations · 4 hit papers
73 papers, 2.5k citations indexed

About

Meena B. Bansal is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Meena B. Bansal has authored 73 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Epidemiology, 35 papers in Hepatology and 13 papers in Surgery. Recurrent topics in Meena B. Bansal's work include Liver Disease Diagnosis and Treatment (42 papers), Liver physiology and pathology (15 papers) and Hepatitis B Virus Studies (14 papers). Meena B. Bansal is often cited by papers focused on Liver Disease Diagnosis and Treatment (42 papers), Liver physiology and pathology (15 papers) and Hepatitis B Virus Studies (14 papers). Meena B. Bansal collaborates with scholars based in United States, United Kingdom and Spain. Meena B. Bansal's co-authors include Scott L. Friedman, Rebecca Taub, Maria Isabel Fiel, Naim Alkhouri, Stephen A. Harrison, Yedidya Saiman, Mustafa R. Bashir, Cynthia D. Guy, Brent A. Neuschwander‐Tetri and Juan P. Frías and has published in prestigious journals such as The Lancet, Nucleic Acids Research and Nature Medicine.

In The Last Decade

Meena B. Bansal

62 papers receiving 2.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

2019 536 citations Stephen A. Harrison, Mustafa R. Bashir et al. profile →
Resmetirom: An Orally Administered, Small-molecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

2023 82 citations Meena B. Bansal et al. touchREVIEWS in Endocrinology profile →
Pathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity

2024 64 citations Meena B. Bansal et al. Alimentary Pharmacology & Therapeutics profile →
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis

2024 55 citations Mazen Noureddin, Michael Charlton et al. Clinical Gastroenterology and Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Meena B. Bansal United States	24	1.6k	1.2k	494	379	338	73	2.5k
Heike Bantel Germany	30	2.1k 1.3×	1.2k 1.0×	500 1.0×	468 1.2×	732 2.2×	77	3.3k
Dong Hyeon Lee South Korea	27	1.6k 1.0×	1.2k 1.0×	264 0.5×	335 0.9×	515 1.5×	129	2.6k
Kristian Bjøro Norway	27	1.9k 1.2×	1.6k 1.4×	429 0.9×	592 1.6×	290 0.9×	79	3.0k
Martin Schlattjan Germany	17	1.1k 0.7×	561 0.5×	271 0.5×	289 0.8×	387 1.1×	34	1.6k
F. Pons‐Romero Spain	21	1.6k 1.0×	934 0.8×	369 0.7×	346 0.9×	374 1.1×	61	2.1k
Michelle Lai United States	23	2.1k 1.3×	1.5k 1.3×	631 1.3×	712 1.9×	435 1.3×	54	2.8k
Hirofumi Uto Japan	34	2.0k 1.2×	1.6k 1.3×	596 1.2×	624 1.6×	737 2.2×	128	4.0k
Oreste Lo Iacono Italy	27	2.1k 1.3×	1.5k 1.2×	256 0.5×	470 1.2×	291 0.9×	60	2.6k
Yongning Xin China	23	1.1k 0.6×	475 0.4×	381 0.8×	427 1.1×	332 1.0×	89	1.9k
Robert Schierwagen Germany	29	1.4k 0.9×	1.2k 1.0×	181 0.4×	491 1.3×	466 1.4×	91	2.3k

Countries citing papers authored by Meena B. Bansal

Since Specialization

Citations

This map shows the geographic impact of Meena B. Bansal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meena B. Bansal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meena B. Bansal more than expected).

Fields of papers citing papers by Meena B. Bansal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meena B. Bansal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meena B. Bansal. The network helps show where Meena B. Bansal may publish in the future.

Co-authorship network of co-authors of Meena B. Bansal

This figure shows the co-authorship network connecting the top 25 collaborators of Meena B. Bansal. A scholar is included among the top collaborators of Meena B. Bansal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meena B. Bansal. Meena B. Bansal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Bing, Meena B. Bansal, Saleh A. Alqahtani, et al.. (2025). Guideline-directed medical strategies for the co-management of heart failure and metabolic dysfunction-associated steatotic liver disease. Communications Medicine. 5(1). 312–312.

Noureddin, Mazen, Mary E. Rinella, Rebecca Taub, et al.. (2025). Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial. Alimentary Pharmacology & Therapeutics. 62(11-12). 1089–1099. 2 indexed citations

Petrazzini, Ben Omega, Áine Duffy, Ghislain Rocheleau, et al.. (2025). Trans-ancestral rare variant association study with machine learning-based phenotyping for metabolic dysfunction-associated steatotic liver disease. Genome biology. 26(1). 50–50. 3 indexed citations

Im, Gene Y., Amon Asgharpour, Elizabeth S. Aby, et al.. (2025). Medications for Weight Loss and MASLD. Journal of Clinical Gastroenterology.

Bansal, Meena B., et al.. (2024). Heavy metals are liver fibrosis risk factors in people without traditional liver disease etiologies. Journal of Environmental Sciences. 155. 329–342. 1 indexed citations

Bansal, Meena B., et al.. (2024). Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature. Journal of Pediatric Gastroenterology and Nutrition. 79(2). 229–237. 10 indexed citations

Noureddin, Mazen, Michael Charlton, Stephen A. Harrison, et al.. (2024). Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis. Clinical Gastroenterology and Hepatology. 22(12). 2367–2377. 55 indexed citations breakdown →

Yip, Rowena, Mark Woodward, Sara Lewis, et al.. (2024). Mixture analysis of associations between environmental and workplace toxins and liver damage and telomere length, stratified by race/ethnicity. Journal of Environmental Sciences. 155. 316–328. 1 indexed citations

Harrison, Stephen A., Vlad Ratziu, Quentin M. Anstee, et al.. (2023). Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 59(1). 51–63. 56 indexed citations

10.

Yip, Rowena, Sara Lewis, Amreen Dinani, et al.. (2023). Environmental exposures are important risk factors for advanced liver fibrosis in African American adults. JHEP Reports. 5(4). 100696–100696. 23 indexed citations

11.

Bansal, Meena B., et al.. (2023). Resmetirom: An Orally Administered, Small-molecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. touchREVIEWS in Endocrinology. 19(1). 60–60. 82 indexed citations breakdown →

12.

Volk, Michael L., Christina Clarke, Sumeet K. Asrani, et al.. (2022). Cirrhosis Quality Collaborative. Clinical Gastroenterology and Hepatology. 20(5). 970–972. 9 indexed citations

13.

Kwon, Sophia, et al.. (2019). A CLASSIC VIEW OF AMIODARONE PULMONARY TOXICITY. CHEST Journal. 156(4). A2131–A2131.

14.

Bansal, Meena B. & Naichaya Chamroonkul. (2018). Antifibrotics in liver disease: are we getting closer to clinical use?. Hepatology International. 13(1). 25–39. 32 indexed citations

15.

Saiman, Yedidya, Tatsuki Sugiyama, Noa Simchoni, Carlo Spirlı̀, & Meena B. Bansal. (2015). Biliary Epithelial Cells Are Not the Predominant Source of Hepatic CXCL12. American Journal Of Pathology. 185(7). 1859–1866. 5 indexed citations

16.

Feng, Hong, Yedidya Saiman, Chuanping Si, Arevik Mosoian, & Meena B. Bansal. (2012). X4 Human Immunodeficiency Virus Type 1 gp120 Promotes Human Hepatic Stellate Cell Activation and Collagen I Expression through Interactions with CXCR4. PLoS ONE. 7(3). e33659–e33659. 29 indexed citations

17.

Sood, Ajit, et al.. (2007). Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis.. PubMed. 25(6). 283–5. 11 indexed citations

18.

Safadi, Rifaat, M Ohta, Carlos E. Alvarez, et al.. (2004). Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology. 127(3). 870–882. 186 indexed citations

19.

Subbaramaiah, Kotha, Nitin Telang, Meena B. Bansal, Babette B. Weksler, & Andrew J. Dannenberg. (1997). Cyclooxygenase‐2 Gene Expression is Upregulated in Transformed Mammary Epithelial Cells^a. Annals of the New York Academy of Sciences. 833(1). 179–185. 16 indexed citations

20.

Thadepalli, H, D Mathai, Seng‐Kee Chuah, & Meena B. Bansal. (1989). Ciprofloxacin versus Ceftazidime in Skin and Soft Tissue Infections. Journal of Chemotherapy. 1(1). 30–34. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact